| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8790118 | Urologic Oncology: Seminars and Original Investigations | 2018 | 6 Pages | 
Abstract
												PN was associated with a significantly better OS than RN for cT1b but not cT2 RCC. PN had a higher 30-day readmission rate than RN in these tumors and appropriate patient selection is crucial. These results require further validation, ideally via randomized trials.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Vivek M.D., Tulay Ph.D., Feng Ph.D., Bruno M.D., Nachiketh Soodana M.D., Sanjaya M.D., Sanoj M.D., Chad M.D., Mark M.D., Dipen M.D., 
											